Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 151
Filter
1.
Vet Microbiol ; 258: 109121, 2021 Jul.
Article in English | MEDLINE | ID: mdl-34020174

ABSTRACT

This study compares the utility of a commercially available multiplex q-PCR assay for serotyping A1, A2, and A6 M. haemolytica serotypes with indirect hemagglutination, for determining the relative distribution of M. haemolytica capsular types associated with respiratory disorders in cattle, sheep, and goats. For the 129 isolates analyzed, both q-PCR and IHA assays exhibited nearly complete agreement for capsular types A1 (k = 0.965) and A2 (k = 0.888) and substantial agreement for A6 (k = 0.801). Despite the overall good performance of the commercial q-PCR, its effectiveness differed between the host origin of the isolates. The serotype was identified by q-PCR in 83.3 % of cattle, 77.8 % of goat, and 53.8 % of sheep isolates. Combining the results of both methods, A1 was the most prevalent in cattle and sheep (55.6 % and 22.25 %, respectively) but was not detected in goats, A2 was the most prevalent in goats (61.1 %) and the second most prevalent in cattle (16.7 %) and sheep (20.5 %). The prevalence of A6 was 7.4 %, 5.1 %, and 16.7 % in cattle, sheep, and goats, respectively. Other capsular types determined exclusively by IHA were A16 in cattle, A9 in goats, and A7, A8, A9, and A13 in sheep. Capsular type diversity was greater in sheep (H = 0.601) than in cattle (H = 0.408) and goat (H = 0.330) isolates. The commercial multiplex q-PCR is a valuable tool, alternative to IHA, for identifying isolates of capsular types A1, A2, and A6, the most frequent serotypes of M. haemolytica associated with respiratory disease in ruminants. However, when testing sheep isolates it should be complemented with immunological assays due to the wider range of serotypes implicated.


Subject(s)
Bacterial Capsules/classification , Cattle Diseases/microbiology , Goat Diseases/microbiology , Mannheimia haemolytica/classification , Sheep Diseases/microbiology , Animals , Cattle , Cattle Diseases/epidemiology , Goat Diseases/epidemiology , Goats , Multiplex Polymerase Chain Reaction/methods , Multiplex Polymerase Chain Reaction/veterinary , Real-Time Polymerase Chain Reaction/methods , Real-Time Polymerase Chain Reaction/veterinary , Sheep , Sheep Diseases/epidemiology , Spain/epidemiology
2.
J Virol Methods ; 251: 118-122, 2018 01.
Article in English | MEDLINE | ID: mdl-29024672

ABSTRACT

Since its emergence, variant RHDV (RHDVb/RHDV2) has spread throughout the Iberian Peninsula aided by the apparent lack of cross protection provided by classic (genogroup 1; G1) strain derived vaccines. In addition to RHDVb, full-length genome sequencing of RHDV strains has recently revealed the circulation of recombinant viruses on the Iberian Peninsula. These recombinant viruses contain the RHDVb structural protein encoding sequences and the non-structural coding regions of either pathogenic RHDV-G1 strains or non-pathogenic (np) rabbit caliciviruses. The aim of the work was twofold: firstly to validate a diagnostic real time RT-PCR developed in 2012 for the detection of RHDVb strains and secondly, to design a conventional RT-PCR for the differentiation of RHDVb strains from RHDVb recombinants by subsequent sequencing of the amplicon.


Subject(s)
Caliciviridae Infections/veterinary , Genetic Variation , Hemorrhagic Disease Virus, Rabbit/classification , Hemorrhagic Disease Virus, Rabbit/isolation & purification , Polymerase Chain Reaction/methods , Rabbits/virology , Animals , Caliciviridae Infections/virology , Hemorrhagic Disease Virus, Rabbit/genetics , Recombination, Genetic , Spain
3.
Vascul Pharmacol ; 80: 35-42, 2016 May.
Article in English | MEDLINE | ID: mdl-26471832

ABSTRACT

Resistance arteries play a key role in the control of local blood flow. They undergo outward remodeling in response to a chronic increase in blood flow as seen in collateral artery growth in ischemic disorders. We have previously shown that mesenteric artery outward remodeling depends on the endothelial estrogen receptor alpha. As outward arterial remodeling is associated with improved endothelium-dependent dilation, we hypothesized that estrogens might also play a role in flow-mediated improvement of endothelium-dependent dilation. Local increase in blood flow in first order mesenteric arteries was obtained after ligation of adjacent arteries in three-month old ovariectomized female rats treated with 17-beta-estradiol (OVX+E2) or vehicle (OVX). After 2 weeks, diameter was equivalent in high flow (HF) than in normal flow (NF) arteries with a greater wall to lumen ratio in HF vessels in OVX rats. Acetylcholine-mediated relaxation was lower in HF than in NF vessels. eNOS and caveolin-1 expression level was equivalent in HF and NF arteries. By contrast, arterial diameter was 30% greater in HF than in NF arteries and the wall to lumen ratio was not changed in OVX+E2 rats. Acetylcholine-mediated relaxation was higher in HF than in NF arteries. The expression level of eNOS was higher and that of caveolin-1 was lower in HF than in NF arteries. Acetylcholine (NO-dependent)-mediated relaxation was partly inhibited by the NO-synthesis blocker L-NAME in OVX rats whereas L-NAME blocked totally the relaxation in OVX+E2 rats. Endothelium-independent relaxation (sodium nitroprusside) was equivalent in OXV and OVX+E2 rats. Similarly, serotonin- and phenylephrine-mediated contractions were higher in HF than in NF arteries in both OVX and OVX+E2 rats in association with high ratio of phosphorylated ERK1/2 to ERK1/2. Thus, we demonstrated the essential role of endogenous E2 in flow-mediated improvement of endothelium (NO)-mediated dilatation in rat mesenteric arteries.


Subject(s)
Blood Flow Velocity/drug effects , Endothelium, Vascular/drug effects , Estradiol/pharmacology , Estrogens/pharmacology , Mesenteric Arteries/drug effects , Vasodilation/drug effects , Animals , Blotting, Western , Caveolin 1/genetics , Endothelium, Vascular/metabolism , Endothelium, Vascular/pathology , Female , Nitric Oxide Donors/pharmacology , Nitric Oxide Synthase Type III/genetics , Nitroprusside/pharmacology , Ovariectomy , Rats, Wistar , Vascular Remodeling/drug effects , Vascular Resistance/drug effects
4.
Prog Urol ; 25(11): 628-35, 2015 Sep.
Article in French | MEDLINE | ID: mdl-25682178

ABSTRACT

OBJECTIVE: To conduct a literature review of the efficiency of vaginal local estrogenotherapy (LE) on genitourinary disorders related to menopause and those side effects. MATERIALS: A literature review was conducted using Pubmed database using the keywords vaginal estrogen, urinary incontinence, urgency, urinary tract infection, vulvar and vaginal atrophy, dyspareunia, breast cancer, endometrial cancer, thrombosis. The most relevant articles were selected and analyzed. RESULTS: The LE demonstrates its efficiency on preventing urinary tract infections, treatment of overactive bladder and vaginal disorders of postmenopausal women in controlled studies or meta-analysis level of evidence 1. Local side effects (discharge, erythema, vaginal bleeding, etc.) are rare. The systemic diffusion of low dose LE is limited and allowed to prescribe it to postmenopausal women without special supervision. However, using LE might be avoided in women with a history of oncological breast due to the lack of controlled studies evaluating the risk of developing breast cancer under LE. Except for high-risk women, LE does not increase the risk of thrombosis. CONCLUSION: Vaginal administration of low dose of estrogen is an effective and safe treatment in the management of postmenopausal genitourinary disorders. However, using LE for women with history of breast cancer or high risk of thrombisis should be avoided.


Subject(s)
Estrogens/administration & dosage , Urinary Incontinence/drug therapy , Urinary Tract Infections/drug therapy , Administration, Topical , Female , Humans , Menopause
5.
Minerva Anestesiol ; 81(10): 1096-104, 2015 Oct.
Article in English | MEDLINE | ID: mdl-25424169

ABSTRACT

BACKGROUND: Chest wall mechanics can be abnormal in patients with acute respiratory disease syndrome (ARDS). Therefore, partitioning respiratory system between lungs and chest wall at the bedside is useful to optimize ventilator settings. A non-invasive method for assessing lung elastance (EL), called lung barometry, was previously described on an animal model. METHODS: This prospective study was designed to compare EL assessed by lung barometry (ELLB) versus esophageal pressure (ELPeso). In sedated, paralyzed patients, PEEP was progressively increased from 5 to 40cmH2O then decreased from 40 to 5cmH2O by step of 5cmH2O every two minutes. ELLB was assessed for each step as the ratio between the change in PEEP and the induced end-expiratory lung volume change measured by direct spirometry. ELPeso was calculated from esophageal pressure measurement at each PEEP. EL and the ratio between EL and respiratory system elastance (ERS) calculated with the two methods were compared. RESULTS: Twenty six adult patients with early onset moderate or severe ARDS were included. There was a linear correlation between ELLB and ELPeso during the increase and decrease of PEEP (R²=0.26 and 0.42, respectively). Concordance using Bland and Altman method demonstrated bias and large limits of agreement during the increase (-0.5 cmH2O/L; -25 to 24 cmH2O/L) and during the decrease in PEEP (-0.3 cmH2O/L; -21 to 20 cmH2O/L). There were no linear correlation between ELLB/ERS and ELPeso/ERS during the increase and the decrease of PEEP (R²=0.00; R²=0.00, respectively). CONCLUSION: In ARDS patients, lung barometry method cannot be used instead of the esophageal pressure measurement to assess EL.


Subject(s)
Elasticity Imaging Techniques/methods , Lung/diagnostic imaging , Respiratory Distress Syndrome/diagnostic imaging , Adolescent , Adult , Aged , Elasticity , Female , Humans , Male , Middle Aged , Positive-Pressure Respiration , Prospective Studies , Young Adult
6.
Am J Physiol Heart Circ Physiol ; 307(4): H504-14, 2014 Aug 15.
Article in English | MEDLINE | ID: mdl-24929854

ABSTRACT

In resistance arteries, a chronic increase in blood flow induces hypertrophic outward remodeling. This flow-mediated remodeling (FMR) is absent in male rats aged 10 mo and more. As FMR depends on estrogens in 3-mo-old female rats, we hypothesized that it might be preserved in 12-mo-old female rats. Blood flow was increased in vivo in mesenteric resistance arteries after ligation of the side arteries in 3- and 12-mo-old male and female rats. After 2 wk, high-flow (HF) and normal-flow (NF) arteries were isolated for in vitro analysis. Arterial diameter and cross-sectional area increased in HF arteries compared with NF arteries in 3-mo-old male and female rats. In 12-mo-old rats, diameter increased only in female rats. Endothelial nitric oxide synthase expression and endothelium-mediated relaxation were higher in HF arteries than in NF arteries in all groups. ERK1/2 phosphorylation, NADPH oxidase subunit expression levels, and arterial contractility to KCl and to phenylephrine were greater in HF vessels than in NF vessels in 12-mo-old male rats only. Ovariectomy in 12-mo-old female rats induced a similar pattern with an increased contractility without diameter increase in HF arteries. Treatment of 12-mo-old male rats and ovariectomized female rats with hydralazine, the antioxidant tempol, or the angiotensin II type 1 receptor blocker candesartan restored HF remodeling and normalized arterial contractility in HF vessels. Thus, we found that FMR of resistance arteries remains efficient in 12-mo-old female rats compared with age-matched male rats. A balance between estrogens and vascular contractility might preserve FMR in mature female rats.


Subject(s)
Estrogens/metabolism , Mesenteric Arteries/physiology , Vascular Remodeling , Vascular Resistance , Age Factors , Animals , Benzimidazoles/pharmacology , Biphenyl Compounds , Cyclic N-Oxides/pharmacology , Estrogens/pharmacology , Female , Hydralazine/pharmacology , Male , Mesenteric Arteries/drug effects , Mesenteric Arteries/growth & development , Mesenteric Arteries/metabolism , Mitogen-Activated Protein Kinase 1/metabolism , Mitogen-Activated Protein Kinase 3/metabolism , NADPH Oxidases/metabolism , Nitric Oxide Synthase Type III/genetics , Nitric Oxide Synthase Type III/metabolism , Rats , Rats, Wistar , Spin Labels , Tetrazoles/pharmacology , Vasoconstriction , Vasoconstrictor Agents/pharmacology , Vasodilation , Vasodilator Agents/pharmacology
7.
Prog Urol ; 23(11): 926-35, 2013 Sep.
Article in French | MEDLINE | ID: mdl-24010923

ABSTRACT

GOAL: The aim was to review the literature on nitric oxide and female lower urinary tract. MATERIAL: A literature review through the PubMed library until December, 31 2012 was carried out using the following keywords: lower urinary tract, bladder, urethra, nervous central system, innervation, female, women, nitric oxide, phosphodiesterase, bladder outlet obstruction, urinary incontinence, overactive bladder, urinary tract infection. RESULTS: Two nitric oxide synthase isoforms, the neuronal (nNOS) and the endothelial (eNOS), are constitutively expressed in the lower urinary tract. Nevertheless, nNOS is mainly expressed in the bladder neck and the urethra. In the bladder, NO modulates the afferent neurons activity. In pathological condition, inducible NOS expression induces an increase in detrusor contractility and bladder wall thickness and eNOS facilitates Escherichia coli bladder wall invasion inducing recurrent urinary tract infections. In the urethra, NO play a major role in smooth muscle cells relaxation. CONCLUSION: The NO pathway plays a major role in the female lower urinary tract physiology and physiopathology. While it acts mainly on bladder outlet, in pathological condition, it is involved in bladder dysfunction occurrence.


Subject(s)
Nitric Oxide Synthase Type III/metabolism , Nitric Oxide Synthase Type I/metabolism , Nitric Oxide/metabolism , Signal Transduction , Urethra/enzymology , Urinary Bladder/enzymology , Biomarkers/metabolism , Female , Humans , Metabolic Networks and Pathways , Nitric Oxide Synthase/biosynthesis , Phosphoric Diester Hydrolases/metabolism , Urethra/innervation , Urethra/physiopathology , Urinary Bladder/innervation , Urinary Bladder/physiopathology , Urinary Bladder Neck Obstruction/enzymology , Urinary Bladder, Overactive/enzymology , Urinary Incontinence/enzymology , Urinary Tract/enzymology , Urinary Tract Infections/enzymology , Urinary Tract Physiological Phenomena
8.
Prog Urol ; 23(8): 502-10, 2013 Jun.
Article in French | MEDLINE | ID: mdl-23725580

ABSTRACT

GOAL: The aim was to review the literature on estrogens and lower urinary tract. MATERIAL: A review of literature through the PubMed library until December 31, 2012 was carried out using the following keywords: lower urinary tract, bladder, urethra, nervous central system, innervation, female, women, estrogen, estradiol, urogenital atrophy, urinary incontinence, overactive bladder, urinary tract infection. RESULTS: On the bladder, estrogens are involved in the trophicity, vascularisation, alpha-adrenergic, cholinergic and muscarinic receptor density, detrusor contractility and inflammation. On the urethra, they impact vascularisation, contractility, urethral pulse and tone, anatomical and functional length. On the neurological control, they act on capsaicin-sensitive afferent fibres, neurological regeneration, nerve growth factor expression and viscerovisceral sensitisation. CONCLUSION: Estrogens play a major role on the lower urinary tract physiology and physiopathology both on the urethra and the bladder.


Subject(s)
Estrogens/physiology , Female Urogenital Diseases/physiopathology , Urinary Tract Physiological Phenomena , Female , Humans , Receptors, Estrogen/physiology
9.
Arterioscler Thromb Vasc Biol ; 33(3): 605-11, 2013 Mar.
Article in English | MEDLINE | ID: mdl-23288162

ABSTRACT

OBJECTIVE: Flow- (shear stress-)mediated outward remodeling of resistance arteries is involved in collateral growth during postischemic revascularization. As this remodeling is especially important during pregnancy, we hypothesized that estrogens may be involved. A surgical model eliciting a local increase in blood flow in 1 mesenteric resistance artery was used in 3-month-old ovariectomized female rats either treated with 17-ß-estradiol (E2) or left untreated. METHODS AND RESULTS: After 14 days, arterial diameter was greater in high-flow arteries than in normal-flow vessels. An ovariectomy suppressed high-flow remodeling, while E2 restored it. High-flow remodeling was absent in mice lacking the estrogen receptor α but not estrogen receptor ß. The kinetics of inflammatory marker expression, macrophage infiltration, oxidative stress, and metaloproteinases expression were not altered by the absence of E2 after 2 and 4 days, that is, during remodeling. Nevertheless, E2 was required for the increase in endothelial nitric oxide synthase expression and activation at day 4 when diameter expansion occurs. Finally, the impact of E2 on the endothelium appeared crucial for high-flow remodeling, as this E2 action was abrogated in mice lacking endothelial NOS, as well as in Tie2-Cre(+) ERα(f/f) mice. CONCLUSIONS: We demonstrate the essential role of E2 and endothelial estrogen receptor α in flow-mediated remodeling of resistance arteries in vivo.


Subject(s)
Endothelial Cells/metabolism , Estradiol/administration & dosage , Estrogen Receptor alpha/agonists , Estrogen Replacement Therapy , Mesenteric Arteries/drug effects , Vascular Resistance/drug effects , Animals , Blood Pressure/drug effects , Caveolin 1/metabolism , Endothelial Cells/drug effects , Estrogen Receptor alpha/deficiency , Estrogen Receptor alpha/genetics , Estrogen Receptor beta/deficiency , Estrogen Receptor beta/genetics , Female , Mesenteric Arteries/metabolism , Mice , Mice, Inbred C57BL , Mice, Knockout , Nitric Oxide/metabolism , Nitric Oxide Synthase Type III/deficiency , Nitric Oxide Synthase Type III/genetics , Ovariectomy , Phosphorylation , Rats , Rats, Wistar , Regional Blood Flow/drug effects , Splanchnic Circulation/drug effects , Time Factors , Vasodilation/drug effects
10.
Ann Fr Anesth Reanim ; 30(4): 335-41, 2011 Apr.
Article in French | MEDLINE | ID: mdl-21411266

ABSTRACT

OBJECTIVES: To study efficacy, systemic and cerebral haemodynamic, and cost of sedation with sevoflurane after midazolam failure. STUDY DESIGN: Prospective observational study in a mixed intensive care unit. PATIENTS AND METHODS: Mechanically ventiled patients in whom deep sedation failed (Ramsay score<5 despite midazolam 10mg/h and fentanyl 400µg/h) were enrolled. Sedation with sevoflurane and fentanyl (200µg/h) was performed during 48 hours. Sevoflurane was administered with a dedicated filter (AnaConDa™) and sevoflurane infusion rate was adjusted in order to achieve a Ramsay score ≥5. Ramsay score, mean arterial blood pressure, norepinephrine dose/24h, intracranial pressure and cerebral perfusion pressure in patients with brain injury were measured. Directs costs for sedation were calculated. An analysis of variance for repeated measures compared values between D0 (intravenous sedation), D1 and D2 (inhaled sedation). RESULTS: Twenty-five patients (age=51 [38-63], SAPS II=43 [33-49]) were enrolled. Ramsay score was 4 [4,5] at D0 and 6 [6] at D1 and D2 (P<0.05 vs D0). Mean arterial pressure was significantly lower at D1 (80 [73-86] mmHg) as compared to D0 (84 [77-92] mmHg) and D2 (84 [78-91] mmHg) (P<0,05). Norepinephrine consumption was lower at D2 as compared to D1 (P<0,05). Intracranial pressure was lower at D1 (9 [5-13] mmHg) and D2 (11 [7-15] mmHg) as compared to D0 (12 [7-17] mmHg) (P<0.05). PPC was stable at D1 and increased at D2. Directs costs were significantly increased with sevoflurane. CONCLUSION: Sevoflurane is an effective and safe alternative to midazolam in ICU patients associated with a moderate increase in costs.


Subject(s)
Anesthetics, Inhalation/therapeutic use , Deep Sedation/methods , Intensive Care Units/economics , Methyl Ethers/therapeutic use , Adult , Anesthetics, Inhalation/adverse effects , Anesthetics, Inhalation/economics , Anesthetics, Intravenous/therapeutic use , Blood Pressure/drug effects , Carbon Dioxide/blood , Cerebrovascular Circulation/drug effects , Critical Care/economics , Deep Sedation/adverse effects , Deep Sedation/economics , Female , Fentanyl/therapeutic use , Humans , Hypnotics and Sedatives/therapeutic use , Intracranial Pressure/drug effects , Male , Methyl Ethers/adverse effects , Methyl Ethers/economics , Midazolam/therapeutic use , Middle Aged , Norepinephrine/administration & dosage , Norepinephrine/pharmacology , Propofol , Prospective Studies , Respiration, Artificial , Sevoflurane , Vasoconstrictor Agents/administration & dosage , Vasoconstrictor Agents/pharmacology
12.
Climacteric ; 12 Suppl 1: 12-7, 2009.
Article in English | MEDLINE | ID: mdl-19811234

ABSTRACT

Whereas hormonal therapy (HT) may increase the risk of coronary heart disease (CHD) and stroke in menopausal women, epidemiological studies (protection in premenopausal women) suggest and experimental studies (prevention of fatty streak development in animals) demonstrate a major atheroprotective action of estradiol (E2). The understanding of the deleterious and beneficial effects of estrogens is thus required at both a cellular and molecular level. Both the endothelium and the immuno-inflammatory system play a key role in the development of fatty streak deposit as well as in the rupture of the atherosclerotic plaque. Whereas E2 favors an anti-inflammatory effect in vitro (cultured cells), it rather elicits a pro-inflammatory response in vivo at the level of several subpopulations of the immuno-inflammatory system, which could contribute to plaque destabilization. E2 promotes beneficial actions on the endothelium such as nitric oxide and prostacyclin production. E2 actions are essentially mediated by two molecular targets: estrogen receptor alpha (ER-alpha) and beta (ER-beta), but the former appears to mediate most of the actions of E2 on the endothelium and on the immune system. ER-alpha modulates target gene transcription through two activation functions (AF), AF-1 and AF-2, even though signalling via ER-alpha located at the plasma membrane (responsible for membrane-initiated steroid signalling (MISS)/(extra-genomic)) can also lead to an indirect effect on gene transcription. Recently, we demonstrated that ER-alpha AF-1 is not required for the vasculoprotective actions of E2, whereas it is necessary for the effects of E2 on its reproductive targets. These results suggest that selective estrogen receptor modulators stimulating ER-alpha with minimal activation of ER-alpha AF-1 could retain beneficial vascular actions, while minimizing the sexual effects.


Subject(s)
Endothelium, Vascular/metabolism , Estradiol/pharmacology , Inflammation/physiopathology , Receptors, Estrogen/physiology , Selective Estrogen Receptor Modulators/pharmacology , Animals , Coronary Artery Disease/chemically induced , Coronary Artery Disease/prevention & control , Disease Models, Animal , Endothelium, Vascular/drug effects , Estradiol/adverse effects , Estrogen Replacement Therapy , Female , Humans , Immune System/drug effects , Inflammation/metabolism , Mice , Postmenopause/drug effects , Premenopause/drug effects , Risk Factors
14.
J Pharm Sci ; 97(12): 5061-73, 2008 Dec.
Article in English | MEDLINE | ID: mdl-18425814

ABSTRACT

Literature data relevant to the decision to allow a waiver of in vivo bioequivalence (BE) testing (biowaiver) for the approval of immediate release (IR) solid oral dosage forms containing aciclovir are reviewed. Aciclovir therapeutic use and therapeutic index, pharmacokinetic properties, data related to the possibility of excipient interactions and reported BE/bioavailability (BA) studies were also taken into consideration in order to ascertain whether a biowaiver can be recommended. According to the Biopharmaceutics Classification System (BCS) and considering tablet strengths up to 400 mg, aciclovir would be BCS Class III. However, in some countries also 800 mg tablets are available which fall just within BCS Class IV. Aciclovir seems not to be critical with respect to a risk for bioinequivalence, as no examples of bioinequivalence have been identified. It has a wide therapeutic index and is not used for critical indications. Hence, if: (a) the test product contains only excipients present in aciclovir solid oral IR drug products approved in ICH or associated countries, for instance as presented in this article; and (b) the comparator and the test product both are very rapidly dissolving, a biowaiver for IR aciclovir solid oral drug products is considered justified for all tablet strengths.


Subject(s)
Acyclovir/administration & dosage , Antiviral Agents/administration & dosage , Acyclovir/pharmacokinetics , Administration, Oral , Antiviral Agents/pharmacokinetics , Biological Availability , Therapeutic Equivalency
15.
Clin Exp Pharmacol Physiol ; 35(4): 396-401, 2008 Apr.
Article in English | MEDLINE | ID: mdl-18307728

ABSTRACT

1. Although hormonal therapy (HT) may increase the risk of coronary heart disease (CHD) and stroke in postmenopausal women, epidemiological studies (protection in premenopausal women) suggest and experimental studies (prevention of fatty streak development in animals) demonstrate a major atheroprotective action of estradiol (E2). The understanding of the deleterious and beneficial effects of oestrogens is thus required. 2. The immuno-inflammatory system plays a key role in the development of fatty streak deposit as well as in the rupture of the atherosclerotic plaque. Although E2 favours an anti-inflammatory effect in vitro (cultured cells), it rather elicits a pro-inflammatory response in vivo involving several subpopulations of the immuno-inflammatory system, which could contribute to plaque destabilization. The functional role of several cytokines was explored in hypercholesterolemic mice. The atheroprotective effect of E2 was fully maintained in mice deficient in interferon-g or interleukin-12, as well as IL-10. In contrast, the protective effect of estradiol was abolished and even reversed in hypercholesterolemic mice given a neutralizing anti-transforming growth factor-b (TGF-b) antibody. Endothelium is another important target for E2, since it not only potentiates endothelial nitric oxide and prostacyclin production, but also controls trafficking of the populations of the immuno-inflammatory system. 3. To conclude, the respective actions of oestrogens on the cell populations involved in the pathophysiology of atherothrombosis may be influenced, among others, by the timing of HT initiation, the status of the vessel wall and, as recently demonstrated the status of the TGF-b pathway.


Subject(s)
Atherosclerosis/metabolism , Cytokines/metabolism , Estradiol/metabolism , Estradiol/pharmacology , Animals , Endothelium/metabolism , Female , Gene Deletion , Humans , Hypercholesterolemia , Interferon-gamma/genetics , Interferon-gamma/metabolism , Interleukin-10/genetics , Interleukin-10/metabolism , Interleukin-12/genetics , Interleukin-12/metabolism , Mice , Transforming Growth Factor beta
16.
Arch Mal Coeur Vaiss ; 100(6-7): 554-62, 2007.
Article in English | MEDLINE | ID: mdl-17893638

ABSTRACT

Whereas hormonal replacement/menopause therapy (HRT) in post-menopausal women increases the coronary artery risk, epidemiological studies (protection in pre-menopaused women) suggest and experimental studies (prevention of the development of fatty streaks in animals) demonstrate a major atheroprotective action of estradiol (E2). The understanding of the deleterious and beneficial effects of estrogens is thus required. The immuno-inflammatory system plays a key role in the development of fatty streak deposit as well as in the atherosclerotic plaque rupture. Whereas E2 favors an anti-inflammatory effect in vitro (cultured cells), it rather elicits pro-inflammation in vivo, at the level of several subpopulations of the immuno-inflammatory system, which could contribute to plaque destabilization. Endothelium is another important target for E2, since it stimulates endothelial NO and prostacyclin production, thus promoting beneficial effects of vasorelaxation and platelet aggregation inhibition. Prostacyclin, but not NO, appears to be involved in the atheroprotective effect of E2. Estradiol accelerates also endothelial regrowth, thus favoring vascular healing. Finally, most of these effects of E2 are mediated by estrogen receptor alpha, and are independent of estrogen receptor beta. In summary, a better understanding of the mechanisms of estrogen action is required not only on the normal and atheromatous arteries, but also on innate and adaptive immune responses. This should help cardiovascular disease prevention optimization after menopause. These mouse models should help to screen existing and future Selective Estrogen Receptor Modulators (SERMs).


Subject(s)
Estradiol/pharmacology , Estrogen Replacement Therapy , Animals , Anti-Inflammatory Agents/pharmacology , Coronary Artery Disease/chemically induced , Coronary Artery Disease/prevention & control , Disease Models, Animal , Endothelium, Vascular/drug effects , Estradiol/adverse effects , Female , Humans , Inflammation Mediators/pharmacology , Mice , Postmenopause/drug effects , Premenopause/drug effects , Risk Factors , Selective Estrogen Receptor Modulators/pharmacology
17.
Fundam Clin Pharmacol ; 20(6): 539-48, 2006 Dec.
Article in English | MEDLINE | ID: mdl-17109647

ABSTRACT

Whereas hormone replacement/menopause therapy (HRT) in postmenopausal women increases the coronary artery risk, epidemiological studies (protection in premenopaused women) suggest and experimental studies (prevention of the development of fatty streaks in animals) demonstrate a major atheroprotective action of oestradiol (E2). The understanding of the deleterious and beneficial effects of oestrogens is thus required. The immuno-inflammatory system plays a key role in the development of fatty streak deposit as well as in the rupture of the atherosclerotic plaque. Whereas E2 favours an anti-inflammatory effect in vitro (cultured cells), it rather elicits in vivo a proinflammation at the level of several subpopulations of the immuno-inflammatory system, which could contribute to plaque destabilization. Endothelium is another important target for E2, as it potentiates endothelial NO and prostacyclin production, thus promoting the beneficial effects as vasorelaxation and inhibition of platelet aggregation. Prostacyclin, but not NO, appears to be involved in the atheroprotective effect of E2. E2 also accelerates endothelial regrowth, thus favouring vascular healing. Finally, most of these effects of E2 are mediated by oestrogen receptor alpha, and are independent of oestrogen receptor beta. In summary, a better understanding of the mechanisms of oestrogen action not only on the normal and atheromatous arteries, but also on innate and adaptive immune responses is required and should help to optimize the prevention of cardiovascular disease after menopause. These mouse models should help to screen existing and future selective oestrogen receptor modulators.


Subject(s)
Atherosclerosis/etiology , Estradiol/physiology , Animals , Atherosclerosis/prevention & control , Blood Vessels/drug effects , Endothelium, Vascular/drug effects , Estrogen Receptor alpha/physiology , Female , Humans , Immunity, Cellular/drug effects , Inflammation/chemically induced , Models, Animal
18.
Biochem Soc Trans ; 34(Pt 1): 17-21, 2006 Feb.
Article in English | MEDLINE | ID: mdl-16246170

ABSTRACT

The mRNA coding for FGF-2 (fibroblast growth factor 2), a major angiogenic factor, is translated by an IRES (internal ribosome entry site)-dependent mechanism. We have studied the role of the IRES in the regulation of FGF-2 expression in vivo, under pathophysiological conditions, by creating transgenic mice lines expressing bioluminescent bicistronic transgenes. Analysis of FGF-2 IRES activity indicates strong tissue specificity in adult brain and testis, suggesting a role of the IRES in the activation of FGF-2 expression in testis maturation and brain function. We have explored translational control of FGF-2 mRNA under diabetic hyperglycaemic conditions, as FGF-2 is implied in diabetes-related vascular complications. FGF-2 IRES is specifically activated in the aorta wall in streptozotocin-induced diabetic mice, in correlation with increased expression of endogenous FGF-2. Thus, under hyperglycaemic conditions, where cap-dependent translation is blocked, IRES activation participates in FGF-2 overexpression, which is one of the keys of diabetes-linked atherosclerosis aggravation. IRES activation under such pathophysiological conditions may involve ITAFs (IRES trans-acting factors), such as p53 or hnRNP AI (heterogeneous nuclear ribonucleoprotein AI), recently identified as inhibitory or activatory ITAFs respectively for FGF-2 IRES.


Subject(s)
Fibroblast Growth Factor 2/genetics , Gene Expression Regulation , Peptide Chain Initiation, Translational , Protein Biosynthesis , Animals , Blood Vessels/metabolism , Blood Vessels/pathology , Codon, Initiator , Diabetes Mellitus/genetics , Diabetes Mellitus/metabolism , Fibroblast Growth Factor 2/metabolism , Mice , Mice, Transgenic , Ribosomes/metabolism
19.
Article in English | MEDLINE | ID: mdl-17824172

ABSTRACT

Whereas hormonal replacement/menopause therapy (HRT) in postmenopausal women increases coronary artery disease risk, epidemiological studies (protection in premenopaused women) suggest and experimental studies (prevention of the development of fatty streaks in animals) demonstrate a major atheroprotective action of estradiol (E2). The understanding of the deleterious and beneficial effects of estrogens is thus required. The atheroprotective effect of E2 is absent in mice deficient in mature T and B lymphocytes, demonstrating the crucial role of the endothelium/immune system pair. The immunoinflammatory system appears to play a key role in the development of fatty streak deposit as well as in the rupture of the atherosclerotic plaque. Whereas E2 favors an anti-inflammatory effect in vitro (cultured cells), it elicits in vivo a proinflammation at the level of several subpopulations of the immunoinflammatory system, which could contribute to plaque destabilization. Endothelium appears to be an important target for E2, since it potentiates endothelial NO and prostacyclin production, thus promoting beneficial effects such as vasorelaxation and inhibition of platelet aggregation. Prostacyclin, but not NO, appear to be involved in the atheroprotective effect of E2, which also accelerates endothelial regrowth, thus favoring vascular healing. Finally, most of these E2 effects are mediated by estrogen receptor alpha and are independent of estrogen receptor beta. In summary, a better understanding of the mechanisms of estrogens on the normal and atheromatous arteries is required and should help to optimize the prevention of cardiovascular disease after menopause. These mouse models should help to screen existing and future selective estrogen receptor modulators (SERMs).


Subject(s)
Atherosclerosis/prevention & control , Endothelium, Vascular/drug effects , Estradiol/pharmacology , Animals , Atherosclerosis/etiology , Endothelium, Vascular/physiology , Estrogen Receptor alpha/physiology , Fibroblast Growth Factor 2/physiology , Humans
20.
Presse Med ; 34(19 Pt 1): 1371-2, 2005 Nov 05.
Article in French | MEDLINE | ID: mdl-16292189

ABSTRACT

INTRODUCTION: Trichomonas is a protozoan rarely incriminated in pulmonary or pleural disorders. CASE: An 84-year-old man, under treatment for chronic lymphoid leukemia with hypogammaglobulinemia, was hospitalized for respiratory distress and fever due to bilateral pulmonary and pleural disorders. Direct examination of the bronchoalveolar lavage fluid revealed a flagella protozoan identified as Trichomonas tenax. DISCUSSION: Although Trichomonas is rare in pulmonary disorders, when it occurs, T. tenax appears to be the most common species. Treatment with metronidazole was effective.


Subject(s)
Lung Diseases, Parasitic/diagnosis , Pleural Diseases/parasitology , Trichomonas Infections/diagnosis , Trichomonas/isolation & purification , Aged, 80 and over , Animals , Antiprotozoal Agents/therapeutic use , Humans , Lung Diseases, Parasitic/drug therapy , Male , Metronidazole/therapeutic use , Pleural Diseases/drug therapy , Trichomonas Infections/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...